JPRN-UMIN000029428
Completed
Phase 1
Phase I investigator initiated clinical trial using a novel WT1 peptide vaccine for patients with metastatic pancreatic cancer - Phase I clinical trial using WT1 peptide vaccine for patients with metastatic pancreatic cancer.
Conditionspancreatic cancer
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- pancreatic cancer
- Sponsor
- Wakayama Medical University
- Enrollment
- 6
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •(1\) Interstitial pneumonia or pulmonary fibrosis (2\) Comfirmed or suspicious brain metastatis (3\) Pleural effusion, ascites fluid, or pericardial fluid in need of drainage. (4\) Severe infection or being suspected (5\) Positive for serum HBs Ag or HBV\-DNA (6\) Positive for anti\-HCV or anti\-HIV ab (7\) Patients who require systemic administration of Corticosteroid (8\) Prior DSP\-7888, other WT1 peptides, or WT1 immunotherapy (9\) History of severe allergies to oil products (10\) History of hypersensitivity to paclitaxel, albumin, and gemcitabine (11\) Active another cancer to define the pprognosis (12\) Severe mental disorders (13\) Peripheral neuropathy \>\=CTCAE ver.4\.0JCOG Grade 2 (14\) Uncontrolled heart disease, pulmonary disease, kidney disease, or liver disease. (15\)Myocardial infarction, severe unstable angina pectoris, colonary or peripheral artery bypass, congestive heart failure, cerebrovascular disease, pulmonary embolization, deep vein thrombosis or other severe thromboembolism within 12 months (16\) Bleeding tendency or severe coagulation disorder (17\) Current participation in other clinical trials. (18\) Pregnant females or nursing mothers who can not stop lactation after the recruitment. Patients or partners, who don't attempt to doing contraception during the study period. (19\) The subject who was determined by investigator that being not adequate to participate in the trial.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
The investigator-initiated clinical trial, booster vaccination against COVID-19 (KD-414)Prevention of COVID-19JPRN-jRCT2031210503Koga Michiko160
Recruiting
Phase 1
Phase I investigator-initiated clinical trial against differentiated thyroid cancer using TAH-1005JPRN-jRCT2051210144Watabe Tadashi32
Active, not recruiting
Not Applicable
The investigator-initiated clinical trial, booster vaccination against COVID-19 (KD-414)COVID-19JPRN-jRCT1031210517Koga Michiko160
Recruiting
Phase 1
MIKE-1Patients with untreated, non-resectable pancreatic cancerUnresectable pancreatic cancerD021441JPRN-jRCT2041210056Kawashima Hiroki55
Not yet recruiting
Not Applicable
Investigator-initiated phase I/IIa clinical trial to assess the safety and efficacy of 11beta-HSD1 inhibitor in patients with the refractory Cushing syndrome and subclinical Cushing syndrome.The refractory Cushing syndrome and subclinical Cushing syndrome.JPRN-UMIN000024482Kyushu University Hospital16